The Laboratory of Virology and Chemotherapy of the Katholieke Universiteit Leuven focusses on the development of novel antiviral strategies against a number of RNA viruses including (but not limited to) HCV, flaviviruses (mainly dengue) and picornaviruses (rhinovirus inhibitors for the prevention and treatment of exacerbations of asthma and COPD by these viruses). As partner of the EU FP7 funded project SILVER (Small-molecule Inhibitor Leads Versus Emerging and Neglected Viruses) the laboratory is very active in identifying small molecule inhibitors of yet other (neglected) RNA viruses including rabies (see below). The laboratory was involved in the discovery of the anti-HCV activity of Alisporivir, a compound which was developed to phase III clinical trials at Novartis
Katholieke Universiteit Leuven
02 March 2015
Bookmark the permalink.
- No events
- The world is running out of antibiotics, WHO report confirmsA report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
- WHO condemns attacks on hospitals and health workers in Idlib and HamaMultiple reported attacks on health facilities and personnel today in Syria have killed and injured health workers and disrupted health services for thousands of people. WHO condemns attacks on hospitals and health workers.
- WHO launches new NCDs Progress MonitorGovernments must step up efforts to control noncommunicable diseases (NCDs) to meet globally agreed targets, including preventing the premature deaths of millions of people from these conditions, according to a new WHO report released today. Limited national progress has been made in the fight against NCDs – primarily cardiovascular and chronic respiratory diseases, cancers and […]
- The world is running out of antibiotics, WHO report confirms